Ann: Neuren and Lanstead agree to pause settlements for 120 days, page-65

before Neuren, as an object of acquisition there is the same Acadia, for which the related rumors have been increasingly amplified since a couple of years to date. with the confirmation of the goodness of Nuplazid by the FDA is increasingly strengthened this possibility and the suspicion that the unhappy news of CNN and the accumulation recorded by the Bross brothers following the collapse of the title is now more than a ' hypothesis. Neither does nothing happen on Neuren's side, but it is also probable that Treagus was not so naive to realize an agreement with Acadia without knowing that the CNN news was without foundation and that maybe Acadia would one day become the transit partner towards a big biotech that we have imagined so much. it seems very strange that NEU does not react in the least to the good news and performance of ACAD; logic would impose a positivity on the stock, but instead we even record volumes well below the average and this is perhaps the strangest aspect. it is certain that regardless of everything, if in the next few days the hypothesis of acquisition of Acadia was strengthened, Treagus's idiot or strategy would be nothing short of brilliant; at that point I really believe that the market can no longer pretend nothing.
I do not know about you, but as the holder of the long course of the NEU title, I do not remember such a comforting phase for the company, where there is a partnership that now seems to be quality, money in cash at historic highs and a preliminary drug which has always been cited as very promising.
if all this makes more or less a historical minimum of the price per NEU share and light exchanges, a form of suspicion that you want to make believe the encounter of what is reality, it increasingly meanders in my head.
good luck to those who have had the courage and the patience to continue this adventure.